EUCTR2007-004912-30-SE进行中（未招募）1 期
Modulation of opiate reward by NK1 antagonism: A laboratory based proof of concept study
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects will be eligible if they are aged 18 – 50 years and have current opiate use
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subject will not be eligible if they
- •-currently meet criteria for opiate dependence.
- •-have a positive urine screen for opiates
- •-meet criteria for any other substance dependence disorder except nicotine within the last 12 months
- •-have any ongoing prescription medication other than oral contraceptives or hormone replacement
- •-have any serious medical condition which in the judgment of the investigators makes administration of opiates medically inappropriate.
研究者
相似试验
Unknown
1 期
Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate AbusersOpioid-Related DisordersHeroin DependenceSubstance-Related DisordersNCT00726960Karolinska University Hospital60
招募中
不适用
Study of NK1-receptor antagonist; aprepitant for prevention of nausea and emesis in patients receiving chemotherapy with irinotecan for gastric cancer.Advanced gastric cancerJPRN-UMIN000011962Gastroenterologic Surgery, Kanazawa University55
招募中
不适用
Effect of oral neurokinin-1 antagonist, aprepitant for chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving carboplatin/paclitaxel chemotherapy.JPRN-UMIN000005317Department of gynecology, Fukuoka University Hospital60
已完成
不适用
fMRI study on effect of NK1 antagonist (Aprepitant) on cognitive function in normal subjectsSubstance-related disorders, Mood disorders, Anxiety disordersJPRN-UMIN000004381ippon Medical School20
招募中
2 期
Efficacy of NK1 receptor antagonist (aprepitant) in the cancer chemotherapies for hematologic malignancies.hematologic malignanciesJPRN-UMIN000006690Kagoshima University Hospital, division of Hematology and Immunology40